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(n = 70) were asked to state their preferences between two health
improvements, each with different starting points and magnitude
of change, until the point of indifference was found. The Wil-
coxon signed rank test was used to determine the statistical
signiﬁcance of the differences between health changes that were
of equal value to the respondent. RESULTS: In Experiment I,
where utilities were represented to participants using a visual
analogue scale, all ten comparisons showed that if two health
improvements are of equal magnitude, individuals will place a
greater beneﬁt valuation upon the improvement that has a more
severe initial health state. This evidence was largely reﬂected in
Experiment II, which used the Health Utilities Index: Mark 3
multi-attribute function to represent utilities using a descriptive
method. In Experiment II, eight of the ten comparisons suggested
that this was the case. CONCLUSION: Using experimental tech-
niques, this study was able to show that ‘equal’ health improve-
ments were valued more, when the initial health state was more
severe. Furthermore, a method was developed in order to quan-
tify the effect of starting disease severity, and to develop a ‘modi-
ﬁed QALY gain’ measure for use in economic evaluation.
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OBJECTIVES: Conceptual models, endpoint models, and con-
ceptual frameworks are research tools used by patient reported
outcome (PRO) researchers. The objective of this study was to
understand and clarify the role of each tool and to understand
the relationships between them in relation to making treatment
beneﬁt claims to the FDA. METHODS: Published literature and
expert consultation were used to explore deﬁnitions, develop-
ment strategies, and use of each tool. RESULTS: A conceptual
model is a representation of proposed causal linkages among a
set of concepts. It can be developed from reviewing the literature,
and interviewing patients and clinicians. An endpoint model is a
representation of the relationships between all measures that may
be deﬁned as endpoints (primary or supportive) in a clinical trial.
It is developed from a systematic/comprehensive review of
disease literature and/or a conceptual model, the Target Product
Proﬁle (TPP), clinical experts, and the clinical development team.
A conceptual framework is a representation of the expected
relationships of items within a domain and of domains within a
PRO concept. It is developed during the development of a PRO
and is validated during the process of psychometric validation.
Each of these tools ﬁt together to take researchers from early
drug development through to eventual treatment beneﬁt claim.
CONCLUSION: Each of the models discussed are useful
research tools and the endpoint model and conceptual frame-
works are essential for treatment beneﬁt claims to be made to
the FDA. They can be easily differentiated and their inter-
relationships within the timescale of the drug development and
treatment beneﬁt claim process can be modelled.
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OBJECTIVES: A current challenge for clinicians is to know
when functional health outcomes are clinically meaningful, and
we have used the Reliable Change Index (RCI) with the most
widely used self-report measure of functional health (the SF-36)
for determine it. The aim was to determine a clinically signiﬁcant
change in SF-36 outcomes from pre-to-post-heart transplant.
METHODS: A total of 150 patients from eleven transplant
hospitals in Spain were included in the waiting list and 80 of
them received a heart transplant and were prospectively studied.
Subjective evaluation of HRQoL over time (before and at 12
months postransplantation) was obtained using the Short
Form-36 (SF-36). The differences between pre and postrasplant
were calculated for the clinical records and correlated with the
differences on HRQoL. A standardization of the SF-36 scores
was applied. Two criteria to determine clinical signiﬁcance by the
RCI:1) the pre-post difference score exceeds the RCI and 2)
post-transplant score fall within the range of normative values.
RESULTS: Comparing the individual domains of SF-36 showed
signiﬁcant improvement pre and postransplantation. The corre-
lation between differences in clinical and HRQoL variables
showed that, as large was the difference in NYHA functional
Class, the greater was the improvement on PCS; and as greater
was the improvement on PCS, the younger was the patient. First
and second criterion for clinical signiﬁcance were satisﬁed:
1)Patients had average changes in SF-36 scores that exceeded
the RCI in all dimensions except for bodily pain dimension,
and 2)All postransplantation scores were in the normal range
(between 45 and 55) except Social Functioning dimension. CON-
CLUSION: Patients perceive heart transplant as capable of
improving their HRQoL and were clinical signiﬁcant except for
Bodily Pain and Social Functioning. While the notion of clinical
signiﬁcance is not clearly deﬁned in HRQoL studies, the RCI
method is a usefull strategy for identifying clinically meaningful
SF-36 outcomes.
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OBJECTIVES: As utility-based health measures, the EQ-5D
and HUI3 draw from a different theoretical basis than
psychometrically-derived measures, yet both weighted utilities
and unweighted approaches ﬁnd common application as out-
comes in clinical trials where inferential statistics are applied.
The objective of this study was to compare the statistical prop-
erties of the EQ-5D and HUI3 health state classiﬁer systems
using weighted utility scores (WUS)to using unweighted simple
summary scores (SSS). METHODS: WUS and SSS were calcu-
lated for EQ-5D and Health Utilities Index Mark 3 (HUI3)
health state classiﬁer systems using two longitudinal datasets
(n(stroke) = 124; n(rehabilitation) = 264). Validity was evaluated
using F-statistics from ANOVA-based known groups compari-
sons. Pre/post paired t-tests were used to evaluate responsiveness.
The relative efﬁciency (RE) ratio of for each of the statistics was
calculated between WUS and SSS, with differences outside the
range of 0.8 to 1.25 (e.g. >25%) interpreted as substantial.
RESULTS: Greater statistical power was associated with WUS
groups than SSS in known groups comparisons for EQ-5D (50%
of RE > 1; no substantial differences) and HUI3 (100% of
RE > 1; 75% substantial). WUS tended to be more responsive for
the HUI3 (62.5% of RE > 1; 37.5% substantial), while SSS
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